506 related articles for article (PubMed ID: 17013637)
1. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
Correia CJ; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
[TBL] [Abstract][Full Text] [Related]
2. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
Strain EC; Walsh SL; Bigelow GE
Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
[TBL] [Abstract][Full Text] [Related]
4. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans.
Donny EC; Walsh SL; Bigelow GE; Eissenberg T; Stitzer ML
Psychopharmacology (Berl); 2002 May; 161(2):202-12. PubMed ID: 11981600
[TBL] [Abstract][Full Text] [Related]
5. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence.
Petry NM; Bickel WK; Badger GJ
Clin Pharmacol Ther; 1999 Sep; 66(3):306-14. PubMed ID: 10511067
[TBL] [Abstract][Full Text] [Related]
6. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers.
Mintzer MZ; Correia CJ; Strain EC
Drug Alcohol Depend; 2004 May; 74(2):205-9. PubMed ID: 15099664
[TBL] [Abstract][Full Text] [Related]
7. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.
Rosado J; Walsh SL; Bigelow GE; Strain EC
Drug Alcohol Depend; 2007 Oct; 90(2-3):261-9. PubMed ID: 17517480
[TBL] [Abstract][Full Text] [Related]
8. Effects of buprenorphine/naloxone in opioid-dependent humans.
Stoller KB; Bigelow GE; Walsh SL; Strain EC
Psychopharmacology (Berl); 2001 Mar; 154(3):230-42. PubMed ID: 11351930
[TBL] [Abstract][Full Text] [Related]
9. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.
Strain EC; Stoller K; Walsh SL; Bigelow GE
Psychopharmacology (Berl); 2000 Mar; 148(4):374-83. PubMed ID: 10928310
[TBL] [Abstract][Full Text] [Related]
10. Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans.
Carroll CP; Walsh SL; Bigelow GE; Strain EC; Preston KL
Exp Clin Psychopharmacol; 2006 May; 14(2):109-20. PubMed ID: 16756415
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone.
Jones HE; Johnson RE; Jasinski DR; Milio L
Drug Alcohol Depend; 2005 Apr; 78(1):33-8. PubMed ID: 15769555
[TBL] [Abstract][Full Text] [Related]
12. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S
JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025
[TBL] [Abstract][Full Text] [Related]
13. Opioid dependence: rationale for and efficacy of existing and new treatments.
Fiellin DA; Friedland GH; Gourevitch MN
Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
[TBL] [Abstract][Full Text] [Related]
14. Opioid-induced respiratory effects: new data on buprenorphine.
Dahan A
Palliat Med; 2006; 20 Suppl 1():s3-8. PubMed ID: 16764215
[TBL] [Abstract][Full Text] [Related]
15. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
[TBL] [Abstract][Full Text] [Related]
16. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone.
Seifert J; Metzner C; Paetzold W; Borsutzky M; Passie T; Rollnik J; Wiese B; Emrich HM; Schneider U
Pharmacopsychiatry; 2002 Sep; 35(5):159-64. PubMed ID: 12237786
[TBL] [Abstract][Full Text] [Related]
17. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
Fudala PJ; Bridge TP; Herbert S; Williford WO; Chiang CN; Jones K; Collins J; Raisch D; Casadonte P; Goldsmith RJ; Ling W; Malkerneker U; McNicholas L; Renner J; Stine S; Tusel D;
N Engl J Med; 2003 Sep; 349(10):949-58. PubMed ID: 12954743
[TBL] [Abstract][Full Text] [Related]
18. Early experience with Suboxone maintenance therapy in Hungary.
Demetrovics Z; Farkas J; Csorba J; Németh A; Mervó B; Szemelyácz J; Fleischmann E; Kassai-Farkas A; Petke Z; Oroján T; Rózsa S; Rigó P; Funk S; Kapitány M; Kollár A; Rácz J
Neuropsychopharmacol Hung; 2009 Dec; 11(4):249-57. PubMed ID: 20150662
[TBL] [Abstract][Full Text] [Related]
19. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
Amass L; Pukeleviciene V; Subata E; Almeida AR; Pieri MC; D'Egidio P; Stankova Z; Costa A; Smyth BP; Sakoman S; Wei Y; Strang J
Addiction; 2012 Jan; 107(1):142-51. PubMed ID: 21749526
[TBL] [Abstract][Full Text] [Related]
20. Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing.
Marsch LA; Bickel WK; Badger GJ; Jacobs EA
Drug Alcohol Depend; 2005 Feb; 77(2):195-204. PubMed ID: 15664721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
